|
Design Therapeutics, Inc. (DSGN) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Design Therapeutics, Inc. (DSGN) Bundle
Verbessern Sie Ihre Investitionsauswahl mit dem DCF -Taschenrechner des Design Therapeutics, Inc. (DSGN)! Tauchen Sie in reale Finanzdaten ein, passen Sie Wachstumsprojektionen und -kosten an und beobachten Sie sofort, wie sich diese Modifikationen auf den inneren Wert von Design Therapeutics, Inc. (DSGN) auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -72.9 | -100 | 0 | 0 | -43.23 | -43.23 | -43.23 | -43.23 | -43.23 |
| EBITDA | -.1 | -8.3 | -35.7 | -62.8 | -66.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -16666.67 | -3683628.32 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | 1.9 | .0 | .1 | .5 | .5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 228776.98 | 2212.39 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -2.0 | -8.3 | -35.8 | -63.3 | -66.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -245443.65 | -3685840.71 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | .1 | 36.1 | 384.1 | 330.4 | 281.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | 16.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .1 | 1.1 | 1.4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 4424.78 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | .0 | .1 | 1.3 | -1.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 47345.13 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 2.5 | 1.4 | 1.6 | 3.0 | 1.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 297242.21 | 619026.55 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | -1.5 | -.9 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 0 | -33628.32 | 100 | 100 | 100 | -20 | -20 | -20 | -20 | -20 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -2.0 | -8.3 | -35.8 | -58.6 | -66.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 2.3 | -9.6 | -38.3 | -56.3 | -69.1 | -.5 | .0 | .0 | .0 | .0 |
| WACC, % | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 | 12.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | 0 | |||||||||
| Net Debt | -18 | |||||||||
| Equity Value | 18 | |||||||||
| Diluted Shares Outstanding, MM | 56 | |||||||||
| Equity Value Per Share | 0.32 |
What You Will Receive
- Authentic DSGN Financial Data: Pre-loaded with Design Therapeutics’ historical and projected figures for accurate analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch as Design Therapeutics’ intrinsic value updates in real-time with your modifications.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- Intuitive Design: Clear layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Design Therapeutics, Inc. (DSGN).
- WACC Tool: A pre-configured Weighted Average Cost of Capital calculator with adjustable parameters.
- Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and operational efficiency ratios specific to Design Therapeutics, Inc. (DSGN).
- Interactive Dashboard and Visuals: Graphical representations that encapsulate essential valuation indicators for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Design Therapeutics, Inc.'s (DSGN) pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Analyze the outputs and leverage the results for investment decisions.
Why Choose This Calculator for Design Therapeutics, Inc. (DSGN)?
- Accuracy: Leverages real Design Therapeutics financials for precise data.
- Flexibility: Built to allow users to easily test and adjust inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Design Therapeutics, Inc.'s (DSGN) potential for investment by estimating its fair value.
- CFOs: Utilize a sophisticated DCF model for accurate financial reporting and analysis related to Design Therapeutics, Inc. (DSGN).
- Consultants: Easily customize the template for valuation reports tailored to clients interested in Design Therapeutics, Inc. (DSGN).
- Entrepreneurs: Discover financial modeling techniques employed by leading biotech firms, including Design Therapeutics, Inc. (DSGN).
- Educators: Implement it as a resource for teaching valuation methodologies relevant to the biotech industry, like that of Design Therapeutics, Inc. (DSGN).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Design Therapeutics, Inc. (DSGN) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Design Therapeutics, Inc. (DSGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.